Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 19, 2012

View Archived Issues

Novel compounds acting on urate transporter patented by Ardea Bisociences

Multigene biomarker panels predict early-stage atherosclerosis

MicroRNA expression signature helps predict response to anticancer agent

Clinical data published on prucalopride for chronic intestinal pseudo-obstruction

Jazz Pharmaceuticals merges with Azur Pharma

Constellation Pharmaceuticals enters collaboration

Joint research agreement targets novel biofocused anticancer therapies

Study identifies mediator of drug-induced liver injury and agent to target it

Milestone developments for Novartis' Lucentis and Galvus in China

Novel tyrosine-protein kinase BTK inhibitors disclosed by Bristol-Myers Squibb

Avixgen patents new candidate drugs for HIV infection

Scientists at PAION prepare novel antifibrinolytic thrombomodulin analogues

Altos Therapeutics presents new dopamine receptor antagonists

PROLOR Biotech presents topline data on hGH-CTP

Phase I trial starts for Celldex Therapeutics' CDX-301

Bristol-Myers Squibb patents novel HIV attachment inhibitors

XOMA acquires U.S. rights to Servier franchise

Concert Pharmaceuticals synthesizes novel HCV NS5B inhibitors

Treatment begins in first FDA-cleared Cavatak trial

Research further delineates Kevetrin's mechanism of action

Soligenix reports results on anthrax vaccine

Provectus receives regulatory guidance from FDA for PV-10

FDA approves new pediatric formulations of Viread

FDA issues complete response letter regarding dapagliflozin

Protalex advances phase Ib study of PRTX-100

Wilex completes phase I trial of oral MEK inhibitor

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 9, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 9, 2026.
ADCs’ breakout 2025 and their still-unfinished potential
BioWorld Science
Over the course of the year, and continuing into the latest scientific meetings, an extraordinary breadth of new antibody-drug conjugate (ADC) designs was...
Development and characterization of anti-CD19 in vivo CAR T therapy
BioWorld Science
Shenzhen Grit Biotechnology Co. Ltd. and Shanghai Vitalgen Biopharma Co. Ltd. recently presented their work to develop and evaluate a novel anti-CD19 in vivo CAR...
Preclinical results of anti-ADAMTS13 antibody in acquired von Willebrand syndrome
BioWorld Science
The acquired von Willebrand syndrome (AVWS) is a rare bleeding disorder with laboratory findings similar to those of inherited von Willebrand disease. Researchers...